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Introduction 
 
 Chronic kidney disease (CKD) is defined as abnormalities of kidney structure or 
function with implications for health, which is present for more than 3 months. Kidney 
function is mostly measured by the filtration capacity of the kidneys (glomerular filtration 
rate ‒ GFR), based on the plasma clearance of endogenous creatinine. Based on the 
estimated glomerular filtration rate (eGFR, calculated by GFR estimating equations), 
CKD is classified in five stages: stage 1 (eGFR > 90 ml/min/1.73m2), stage 2 (eGFR 
between 60 and 89 ml/min/1.73m2), stage 3 (eGFR between 30 and 59 ml/min/1.73m2), 
stage 4 (eGFR between 15 and 29 ml/min/1.73m2) and stage 5 (eGFR < 15 
ml/min/1.73m2).  
The prevalence of CKD is increasing each year, the global prevalence of CKD of 
all stages is as high as 13.4% and 10.6% of CKD stages 3-5. The prevalence of CKD of 
all stages is the highest in Europe, compared to other geographical regions. These data 
support that CKD has become a global health and financial burden, so there is an 
increasing need to study CKD development and find new therapeutic ways to slow the 
progression of the disease or even treat chronic renal insufficiency. 
 Although there are CKD cases caused by monogenetic diseases, chronic kidney 
disease is mostly a complex gene environmental disease; several environmental and 
genetic factors affect its development. Diabetes and hypertension are the two most 
important causes which lead to chronic renal insufficiency but CKD development clearly 
has a genetic component. At present, one of the most powerful methods to understand the 
genetics of a complex trait such as CKD is the genome-wide association study (GWAS). 
GWAS examines genetic variants across the human genome to identify associations 
between variants and phenotypes. GWAS divides the population into two groups of 
individuals: one group with a particular disease/parameter, e.g. CKD (cases) and another 
group of otherwise similar people without the parameter (controls). If a variant (single 
nucleotide polymorphism [SNP]) is more frequent in people with the disease, the SNP is 
said to be associated with the disease. GWAS is a very important way to reveal genetic 
variants in the association with CKD, however, further investigations are needed to find 
the functionally relevant polymorphisms. 
 Most of the disease-associated SNPs are located in the non-coding region of the 
genome, therefore their functional role of the disease development is largely unknown. 
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Disease-associated genetic variants can alter binding sites for important transcription 
factors and influence the expression of nearby genes. Genetic variants can potentially 
alter steady-state expression of genes, in which case they interfere with basal transcription 
factor binding or can alter the amplitude of transcript changes after signal-dependent 
transcription factor binding. Genomic loci which can contribute to the variation of gene 
expression levels are called expression quantitative trait loci (eQTL). The examination of 
genetic variations and the transcriptome of the subjects simultaneously can reveal SNPs 
acting as eQTLs. 
 Functional genomics, as a discipline aims to understand the dynamic function of 
the genome, such as transcription, translation, gene expression regulation, protein-protein 
interactions, etc. One of the very important goals of this scientific field is to understand 
and find the function of the non-coding genetic regions where most of the disease-
associated polymorphisms are located. Using system biology approaches of functional 
genomics, the goal of this Ph.D. work was to map the expression of the transcripts near 
the CKD-risk associated loci in normal and disease human kidney samples to identify 
potential causal and/or target genes for prioritization. (Figure 1.) 
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Figure 1. Schematic representation of different experimental designs to understand 
CKD development. 
GWASs examine the relationship between genetic variants (SNP) and disease state (CKD). The 
eQTL analysis examines the relationship between transcript levels and genetic variation in control 
samples. The relationship between transcript levels around CKD risk variants and kidney function 
can be studied by functional genomics. 
CRAT: CKD risk associated transcripts 
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Objectives 
 
We hypothesized that polymorphisms associated with renal disease will influence 
the expression of nearby transcript levels in the kidney. In this Ph.D. work, I mapped the 
expression of these transcripts in normal and disease human kidney samples. I used 
functional genomics and systems biology approaches to investigate tissue-specific 
expression of transcripts and their correlation with kidney function.  
The goals of the Ph.D. work were: 
1. Providing a dataset of potential causal and/or target genes in the vicinity of the CKD 
risk associated loci 
2. Identifying critical pathways associated with kidney function decline for further 
analysis 
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Methods 
 
Human kidney samples 
The human kidney samples were obtained from routine surgical nephrectomies or 
leftover portions of diagnostic kidney biopsies. Only the normal, non-neoplastic part of 
the tissue was used for further investigation. Samples were de-identified, and 
corresponding clinical information was collected by an individual who was not involved 
in the research protocol. The kidney tissue was manually microdissected for glomerular 
and tubular compartment under a microscope. Using fine forceps, the glomeruli were 
removed from the kidney tissue and processed separately. We refer the rest of the kidney 
tissue as “tubules”. To examine gene expression changes, we extracted RNA (ribonucleic 
acid) form 95 tubules and 51 glomeruli samples, furthermore, 41 tubule samples were 
used for external validation. The kidney samples were obtained from a diverse population. 
 
Sample processing and data analysis 
 Dissected tissue was homogenized, and RNA was prepared using RNAeasy mini 
columns (Qiagen, Valencia, CA, USA) according to the manufacturer’s instructions. Only 
samples without evidence of degradation were further used. 
The gene expression profile of the samples was analyzed with the help of 
Affymetrix U133A microarrays and GeneSpring GX software, version 12.6 (Agilent 
Technologies) and additional quantitative real time polymerase chain reaction (QRT-
PCR) was performed for validation and expression quantitative trait loci analysis (eQTL). 
For eQTL analysis, we genotyped the samples after DNA extraction and purification with 
the help of specific TaqMan assay probes. Furthermore, the baseline expression of the 
transcripts was analyzed by RNA sequencing from healthy kidney tissues (n=2). We 
performed immunohistochemistry to examine the expression changes on protein level. 
 
Bioinformatics 
Gene ontology and network analyses were performed (DAVID Bioinformatics 
Resources, Ingenuity Network Analysis) and publicly available data sets were analyzed, 
such as Human Protein Atlas, Illumina Body Map and the eQTL browser of the National 
Institute of Health. 
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Overview of the used statistical methods 
For statistical analysis of the demographic, clinical and histopathological 
parameters, Pearson product moment correlation or Spearman correlation coefficient (R 
coefficient) was used to measure the strength of association between age, BMI (body 
mass index), serum-glucose, blood pressure (systole and diastole), serum-creatinine, 
BUN (Blood urea nitrogen), serum-albumin, percentage of glomerulosclerosis and 
interstitial fibrosis and estimated glomerular filtration rate (eGFR); depending on the 
results of the D'Agostino-Pearson normality tests. The statistical significance of the 
correlation was calculated with two-tailed test (alpha=0.05). To compare the expression 
of the genotyped samples in the eQTL-analysis, one-way ANOVA and Student’s t-test 
were used. The statistical analyses were performed using Prism 6 software (GraphPad, 
La Jolla, CA, USA). 
GeneSpring GX software was used for statistical analysis to process microarray 
data. Pearson product moment correlation was used to measure the strength of association 
between gene expression and eGFR. We used Benjamini–Hochberg multiple testing 
correction with a P value of 0.05. 
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Results 
 
Identifying CKD risk associated transcripts (CRATs) 
To identify CKD risk associated transcripts, we performed manual literature 
search to examine all genome-wide association studies reporting genetic association for 
CKD-related traits. Our literature analysis identified 10 publications which described 
SNPs associated with eGFR (on the basis of serum creatinine or cystatin C calculations) 
or the presence of chronic renal disease. Coding polymorphisms and SNPs that did not 
reach genome-wide significance (P > 5 x 10-8) were excluded from our study. Finally, 44 
tagging SNPs meeting all of these criteria were used for further analysis. Most 
publications did not differentiate cases on the basis of disease etiology and included cases 
with hypertensive and diabetic kidney disease, however, three SNPs associated only with 
diabetic nephropathy, therefore they were also analyzed separately.  
We hypothesized that polymorphisms associated with renal disease will influence 
the expression of nearby transcript levels in the kidney, by altering transcriptional factor 
binding. Previous reports indicate that the majority (70%–80%) of the gene regulatory 
elements (promoters, enhancers, and insulators) are within 250 kb of the gene. Using 
these criteria, we identified 306 genes within 250 kb (upstream or downstream) of 44 
CKD SNPs. There was no gene within the 500-kb window around the rs12437854 SNP; 
therefore, 43 loci were examined. We called these transcripts CKD risk associated 
transcripts (CRATs). 
 
Kidney-specific expression of CRATs 
First, we investigated whether these CRATs have kidney-specific expression. We 
hypothesized that these CRATs play important role in kidney function, therefore they 
should be expressed in the kidney. We used comprehensive RNA sequencing analysis in 
normal, healthy kidney tubule samples (n=2) to determine the baseline expression of the 
306 CRATs. We found that 41% of the CKD risk loci-associated transcripts showed high, 
32% showed medium, 21% showed low expression and only 6% of the transcripts were 
not detectable in healthy human kidney tubule samples. Overall, we found that a large 
percentage of the CKD SNP neighboring transcripts (94%; 287 of 306) were expressed 
in the human kidney. To confirm our results, we used publicly available datasets to 
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examine the kidney-specific expression of CRATs. We performed gene ontology analysis 
(david.abcc.ncifcrf.gov), which indicated that CRATs have specific and significant 
enrichment in the kidney and peripheral leukocytes (P=0.0082 and P=0.0014, 
respectively). Additionally, we compared absolute expression levels of CRATs by RNA 
sequencing in 16 different human organs using the Illumina Body Map database 
(www.ebi.ac.uk). The atlas confirmed the statistically significant kidney-specific 
expression enrichment of CRATs. In summary, expression of CRATs was enriched in the 
kidney and peripheral lymphocytes, potentially indicating the role of these cells in kidney 
disease development. 
 
Expression profile of CRATs in normal and disease human kidney samples 
 According to our hypothesis, the functionally important CRATs are not only 
expressed in relevant cell types (e.g. kidney tubule cells, leukocytes) but the expression 
levels of these CRATs should change in CKD. To test this hypothesis, we analyzed gene 
expression levels in a large collection of microdissected human glomerular (n=51) and 
tubule (n=95) samples. Transcript profiling was performed for each individual sample 
using Affymetrix U133v2 microarrays, and they contained probe set identifications for 
226 transcripts from the 306 original CRATs. 
Linear correlation analysis (Pearson) identified the significant association of 34 
CRATs with eGFR (P < 0.05) in glomerular samples. The correlation between the 
expression of seven CRATs and eGFR remained significant, even after Benjamini–
Hochberg-based multiple testing correction. The expression of multiple novel transcripts 
showed correlation with kidney function. For example, expression levels of Family with 
sequence similarity 47, member E (FAM47E), Plexin domain-containing 1 (PLXDC1), 
Vascular endothelial growth factor A (VEGFA) and Membrane-associated guanylate 
kinase 2 (MAGI2) correlated with eGFR. Interestingly, FAM47E, PLXDC1, and MAGI2 
have not been identified in GWASs as potential causal or target genes in the vicinity of 
CKD risk loci. In summary, the analysis highlighted that the expression of several CRATs 
in glomeruli correlates with renal function. 
We also performed linear correlation tests between the gene expression arrays and 
eGFR in tubule samples. Pearson correlation identified 92 transcripts with statistically 
significant (P < 0.05) linear correlation with kidney function. The correlation between the 
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expression of 70 CRATs and eGFR remained significant, even after Benjamini–
Hochberg-based multiple testing correction. Tubule-specific expression of solute carriers 
had the strongest correlation with renal function in tubules. For example, the levels of the 
Solute carrier family 34, member 1 (SLC34A1), which codes a type II sodium/phosphate 
cotransporter, and SLC7A9 (Solute Carrier Family 7 Member 9), which codes the light 
chain of an amino acid transporter, correlated strongly with eGFR (with R values of 0.61 
and 0.59, respectively). In addition to solute carriers, the expression of a metabolic 
enzyme, the Acyl-CoA synthetase medium chain family member 5 (ACSM5), also highly 
correlated with renal function and showed high protein expression in tubule epithelial 
cells. 
For external validation, we used a gene expression dataset containing genome-
wide transcription profiling from 41 microdissected tubule samples. The samples in this 
dataset were different from the primary dataset. Although this dataset was much smaller 
with a narrower eGFR range, we confirmed the significant linear correlation of 51 
transcripts, highlighting the importance of these CRATs. 
In summary, the gene expression and kidney function correlation analysis 
revealed CRATs for future prioritization. 
 
Transcript levels around the “UMOD-locus” and other CKD risk associated loci 
 We specifically investigated expression changes of the UMOD transcript, because 
it is a potential causal or target gene underlying the polymorphism of some of the best 
characterized CKD associated loci on chromosome 16 (rs12917707, rs4293393 and 
rs11864909). This gene encodes one of the most abundant proteins in human urine: 
Uromodulin or Tamm–Horsfall protein. We found that UMOD transcript levels showed 
a highly significant linear correlation with renal function (Pcorr=6.09 x 10-6) in tubule 
samples. We also performed immunohistochemistry staining from samples used for the 
transcriptomic analysis: samples with low UMOD mRNA expression and with high 
expression. The results of the staining indicate excellent correlation between uromodulin 
protein expression and its transcript levels. 
Although UMOD has emerged as an important causal gene for CKD, 
unexpectedly, we found that other nearby genes were also highly expressed in renal 
tubules, and their expression strongly correlated with eGFR. We observed that ACSM5 
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and ACSM2A/B were also highly expressed in human kidney tubule samples. RNA 
sequencing data from the Illumina Body Map also confirmed the expression levels of 
these transcripts.  By linear correlation analysis, we found highly significant correlation 
between renal function and UMOD, ACSM5 and ACSM2A/2B transcript levels. We also 
validated the transcript expression of the genes near the UMOD locus by QRT-PCR to 
confirm the microarray results. We performed immunohistochemistry staining on 
samples with high and low ACSM2A/2B transcript expression and found the expression 
level changes on protein level as well. ACSM5 and ACSM2A/2B genes (ACSM family 
members) encode three genes in fatty acid oxidation pathways. However, these transcripts 
showed high expression in the kidney and their expression strongly correlated with renal 
function, they were not mentioned before in the GWASs as potential causal or target 
genes. Our results indicate a potential functional role of these transcripts. 
We also examined whether in the proximity of a single SNP could be observed 
changes in expression of a single gene or multiple genes. We found that, on 23 of 43 
examined CKD risk loci, multiple neighboring transcripts correlated with renal function 
indicating that the regulation of these genes could be linked. 
 
Expression quantitative trait loci (eQTL) analysis 
Polymorphisms associated with kidney function can also directly control baseline 
transcript levels in disease-relevant types. Based on the possible cross-tissue similarity in 
eQTL results, we examined whether CKD risk SNPs influence local transcript levels (in 
cis; within 1-Mb distance) in multiple different datasets where genotype and gene 
expression correlation data were available. We found that 4 SNPs from the previously 
identified 44 leading/tagging SNPs and 16 SNPs in their linkage disequilibrium (r2 ≥ 0.8) 
acted as cis-eQTLs for 11 different transcripts (P < 0.05). One of the 11 transcripts, CLTB 
(Clathrin, light chain B) showed significant linear correlation with eGFR in glomerulus 
samples (P=0.016). Another transcript, CERS2 (ceramide synthase 2) was highly also 
correlated with eGFR in tubule samples (P=1.2 x 10-4), making it a potential candidate 
gene for CKD development. 
Although, the main part of our work focuses on the associations between the 
disease, progression and gene expression, we genotyped kidney samples for rs881858 and 
rs6420094 SNPs to search for expression changes affected by these loci. 
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 Tubule-specific VEGFA transcript levels were lower in patients who were 
homozygous for the major allele on the rs881858 locus compared to heterozygous or 
minor allele homozygous samples (P=0.025). However, this association was only true in 
healthy kidney samples (n=21, eGFR > 85 ml/min/1.73m2). Glomerular or tubule-specific 
VEGFA transcript and protein expression levels highly correlated with eGFR. These 
results indicate that the rs881858 polymorphism likely influences VEGFA transcript 
levels, however, this association cannot be observed in samples with kidney disease, 
because of the high influence of disease conditions on VEGFA expression.  These results 
indicate that VEGFA could be an important CKD candidate gene.  
Additionally, we examined whether genetic polymorphism (rs6420094) on 
chromosome 5 around SLC34A1 will influence transcript expression. We found that 
tubule-specific SLC34A1 expression was significantly higher in patients who were 
homozygous for the major allele on the rs6420094 locus compared with heterozygous or 
minor allele homozygous samples (n=18, eGFR > 85 ml/min/1.73m2, P=0.0305). 
 
Network analysis of CRATs 
Taken together, we identified 104 transcripts of 226 CRATs showing significant 
correlation with eGFR at 39 out of the 44 loci. We examined whether the 104 renal 
function-correlating CRATs (either in tubule or glomerular samples) in the neighborhood 
of 39 CKD risk loci show relatedness and can form a network. The network analysis was 
performed separately on genes that showed positive or negative correlation with kidney 
function.  
Genes showing negative correlation with kidney function (higher expression in 
CKD) clustered at the TNF (tumor necrosis factor), TGF-β1 (transforming growth factor 
beta) and NF-κB/RELA (nuclear factor kappa B with p65 subunit) regulatory nodes. Most 
members of this cluster are known to play a role in immune function and regulation of 
inflammation. The second cluster (transcripts with expression that positively correlated 
with kidney function) centered at VEGFA and ERBB2 (Erb-B2 Receptor Tyrosine Kinase 
2) molecules. These molecules play important roles in maintaining epithelial and 
endothelial functions. In summary, network analysis highlighted the relatedness of the 
regulated genes and the potential role of epithelial cell biology and inflammation in CKD. 
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Transcript levels around loci associated with diabetic nephropathy 
We also specifically examined the correlation of the diabetic CKD-associated 
polymorphisms (rs12437854, rs7583877 and rs1617640) and transcript changes in 
glomerular and tubule samples only with normal renal function and diabetic kidney 
disease. After excluding the samples with hypertensive CKD, the analysis was performed 
on 42 glomerular and 76 tubule samples. The analysis highlighted that the expression of 
Procollagen C-endopeptidase enhancer (PCOLCE) in glomerular samples and the 
expression of Thyroid hormone receptor interactor 6 (TRIP6) in tubule samples in the 
vicinity of diabetic CKD SNPs correlate with kidney function. 
Furthermore, genes in the vicinity of rs1326934 locus were examined. In a multi-
stage based GWAS, our group found associations between this locus and diabetic 
nephropathy in patients with type 1 diabetes (Publication II.). However, none of the 
examined SNPs reached genome-wide significance in the discovery cohort, additional 
analysis drew the attention to this locus, which is in the vicinity of the SORBS1 gene 
(Sorbin and SH3 Domain Containing 1).  
We examined the expression of the SORBS1 gene in normal, non-diabetic samples 
and in samples with diabetic kidney disease (17 glomerular and 39 tubule samples). First, 
we performed binary analysis comparing cases versus controls, and found significantly 
higher expression of SORBS1 in tubule samples of diabetic nephropathy (P=6 x 10-4). 
Additional linear correlation analysis revealed a significant inverse correlation between 
SORBS1 expression values and eGFR in tubule samples (R=−0.493; P=1.44 x 10−3). We 
also examined the expression and correlation with eGFR of other nearby genes in the 
vicinity of rs1326934, where not only SORBS1 but other genes also correlated with eGFR. 
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Conclusions 
 
Understanding complex trait development, such as chronic kidney disease, is a 
formidable challenge. As discussed above, CKD is a gene environmental disease with 
several genetic and environmental effects on its development. The first step to understand 
the development of CKD is to interpret the genetic architecture of the disease. 
Recent GWASs have identified several SNPs associated with chronic kidney 
disease, however the functional role of these loci has not revealed yet.  
In this Ph.D. work: 
 
• We identified 306 CKD-risk associated transcripts (CRATs) in the vicinity of 44 
CKD-risk associated loci.  
• We examined the expression of these CRATs in a large set of human normal and 
diseased kidney samples and described the gene expression correlation with 
kidney function.  
• We could highlight genes for further prioritization for 39 of 44 loci (89%).  
• Using UMOD, ACSM2A, and VEGFA genes as examples, we showed that these 
expression changes likely correlate with protein levels.  
• Our results also suggest that not only the closest gene but also, several genes in 
the close vicinity correlate highly with renal function, indicating their potential 
importance and their potential co-regulation.  
• Network analysis of eGFR-correlating CRATs highlighted two major clusters; a 
positive correlation with epithelial and vascular functions and an inverse 
correlation with inflammatory gene cluster.  
 
In summary, we performed a comprehensive functional genomic analysis of 
CKD-associated GWAS hits. These results highlight multiple new CKD risk associated 
candidate genes, that were not originally considered by GWAS experiments. Future 
molecular and cell biology experiments will be needed to understand the functional role 
of these CRATs. Our findings can direct the renal community toward identification of 
genes and pathways that may serve as disease biomarkers or causal pathways. 
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